 | • レポートコード：QYR9ST04483 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療・製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、免疫チェックポイント阻害剤の世界市場について調査・分析し、免疫チェックポイント阻害剤の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（CLTA-4阻害剤、PD-1およびPD-L1阻害剤）、用途別（肺癌、血液癌、腎癌、膀胱癌、黒色腫、ホジキンリンパ腫）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の免疫チェックポイント阻害剤市場動向 ・主要企業別マーケットシェア ・免疫チェックポイント阻害剤の種類別市場規模2014-2019 （CLTA-4阻害剤、PD-1およびPD-L1阻害剤） ・免疫チェックポイント阻害剤の用途別市場規模2014-2019 （肺癌、血液癌、腎癌、膀胱癌、黒色腫、ホジキンリンパ腫） ・免疫チェックポイント阻害剤の北米市場：主要企業・種類別/用途別市場規模 ・免疫チェックポイント阻害剤のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・免疫チェックポイント阻害剤の中国市場：主要企業・種類別/用途別市場規模 ・免疫チェックポイント阻害剤の日本国内市場：主要企業・種類別/用途別市場規模 ・免疫チェックポイント阻害剤の東南アジア市場：主要企業・種類別/用途別市場規模 ・免疫チェックポイント阻害剤のインド市場：主要企業・種類別/用途別市場規模 ・免疫チェックポイント阻害剤の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （Bristol-Myers Squibb Company、AstraZeneca plc、Merck & Co、Pfizer, Inc、F. Hoffmann-La Roche Ltd、Incyte Corporation、NewLink Genetics Corporation、Celldex Therapeutics, Inc、GlaxoSmithKline plc、Seattle Genetics, Inc.） ・免疫チェックポイント阻害剤の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Check point inhibitors are molecules that use the cosmic potential of the immune response system of the body, and its limitless influences to attack the cancer cells present inside the body, as well as avoids relapse of cancer cells. In case any relapse occurs in the body, it can easily be recognized and eliminated by the use of immune memory cells, leaving a healthy tissue. Factors such as rise in incidences of cancer and high rate of associated mortality, increased healthcare expenditures, growth in government initiatives to alleviate cancer, and rise in public awareness boost the growth of immune checkpoint inhibitors market.
In 2018, the global Immune Check Point Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Immune Check Point Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Check Point Inhibitors development in United States, Europe and China.
The key players covered in this study
Bristol-Myers Squibb Company
AstraZeneca plc
Merck & Co
Pfizer, Inc
F. Hoffmann-La Roche Ltd
Incyte Corporation
NewLink Genetics Corporation
Celldex Therapeutics, Inc
GlaxoSmithKline plc
Seattle Genetics, Inc.
Market segment by Type, the product can be split into
CLTA-4 Inhibitors
PD-1 & PD-L1 Inhibitor
Market segment by Application, split into
Lung Cancer
Blood Cancer
Renal Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Immune Check Point Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the Immune Check Point Inhibitors development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Immune Check Point Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Immune Check Point Inhibitors Market Size Growth Rate by Type (2014-2025)
1.4.2 CLTA-4 Inhibitors
1.4.3 PD-1 & PD-L1 Inhibitor
1.5 Market by Application
1.5.1 Global Immune Check Point Inhibitors Market Share by Application (2014-2025)
1.5.2 Lung Cancer
1.5.3 Blood Cancer
1.5.4 Renal Cancer
1.5.5 Bladder Cancer
1.5.6 Melanoma
1.5.7 Hodgkin Lymphoma
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Immune Check Point Inhibitors Market Size
2.2 Immune Check Point Inhibitors Growth Trends by Regions
2.2.1 Immune Check Point Inhibitors Market Size by Regions (2014-2025)
2.2.2 Immune Check Point Inhibitors Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Immune Check Point Inhibitors Market Size by Manufacturers
3.1.1 Global Immune Check Point Inhibitors Revenue by Manufacturers (2014-2019)
3.1.2 Global Immune Check Point Inhibitors Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Immune Check Point Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2 Immune Check Point Inhibitors Key Players Head office and Area Served
3.3 Key Players Immune Check Point Inhibitors Product/Solution/Service
3.4 Date of Enter into Immune Check Point Inhibitors Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Immune Check Point Inhibitors Market Size by Type (2014-2019)
4.2 Global Immune Check Point Inhibitors Market Size by Application (2014-2019)
5 United States
5.1 United States Immune Check Point Inhibitors Market Size (2014-2019)
5.2 Immune Check Point Inhibitors Key Players in United States
5.3 United States Immune Check Point Inhibitors Market Size by Type
5.4 United States Immune Check Point Inhibitors Market Size by Application
6 Europe
6.1 Europe Immune Check Point Inhibitors Market Size (2014-2019)
6.2 Immune Check Point Inhibitors Key Players in Europe
6.3 Europe Immune Check Point Inhibitors Market Size by Type
6.4 Europe Immune Check Point Inhibitors Market Size by Application
7 China
7.1 China Immune Check Point Inhibitors Market Size (2014-2019)
7.2 Immune Check Point Inhibitors Key Players in China
7.3 China Immune Check Point Inhibitors Market Size by Type
7.4 China Immune Check Point Inhibitors Market Size by Application
8 Japan
8.1 Japan Immune Check Point Inhibitors Market Size (2014-2019)
8.2 Immune Check Point Inhibitors Key Players in Japan
8.3 Japan Immune Check Point Inhibitors Market Size by Type
8.4 Japan Immune Check Point Inhibitors Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Immune Check Point Inhibitors Market Size (2014-2019)
9.2 Immune Check Point Inhibitors Key Players in Southeast Asia
9.3 Southeast Asia Immune Check Point Inhibitors Market Size by Type
9.4 Southeast Asia Immune Check Point Inhibitors Market Size by Application
10 India
10.1 India Immune Check Point Inhibitors Market Size (2014-2019)
10.2 Immune Check Point Inhibitors Key Players in India
10.3 India Immune Check Point Inhibitors Market Size by Type
10.4 India Immune Check Point Inhibitors Market Size by Application
11 Central & South America
11.1 Central & South America Immune Check Point Inhibitors Market Size (2014-2019)
11.2 Immune Check Point Inhibitors Key Players in Central & South America
11.3 Central & South America Immune Check Point Inhibitors Market Size by Type
11.4 Central & South America Immune Check Point Inhibitors Market Size by Application
12 International Players Profiles
12.1 Bristol-Myers Squibb Company
12.1.1 Bristol-Myers Squibb Company Company Details
12.1.2 Company Description and Business Overview
12.1.3 Immune Check Point Inhibitors Introduction
12.1.4 Bristol-Myers Squibb Company Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.1.5 Bristol-Myers Squibb Company Recent Development
12.2 AstraZeneca plc
12.2.1 AstraZeneca plc Company Details
12.2.2 Company Description and Business Overview
12.2.3 Immune Check Point Inhibitors Introduction
12.2.4 AstraZeneca plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.2.5 AstraZeneca plc Recent Development
12.3 Merck & Co
12.3.1 Merck & Co Company Details
12.3.2 Company Description and Business Overview
12.3.3 Immune Check Point Inhibitors Introduction
12.3.4 Merck & Co Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.3.5 Merck & Co Recent Development
12.4 Pfizer, Inc
12.4.1 Pfizer, Inc Company Details
12.4.2 Company Description and Business Overview
12.4.3 Immune Check Point Inhibitors Introduction
12.4.4 Pfizer, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.4.5 Pfizer, Inc Recent Development
12.5 F. Hoffmann-La Roche Ltd
12.5.1 F. Hoffmann-La Roche Ltd Company Details
12.5.2 Company Description and Business Overview
12.5.3 Immune Check Point Inhibitors Introduction
12.5.4 F. Hoffmann-La Roche Ltd Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.5.5 F. Hoffmann-La Roche Ltd Recent Development
12.6 Incyte Corporation
12.6.1 Incyte Corporation Company Details
12.6.2 Company Description and Business Overview
12.6.3 Immune Check Point Inhibitors Introduction
12.6.4 Incyte Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.6.5 Incyte Corporation Recent Development
12.7 NewLink Genetics Corporation
12.7.1 NewLink Genetics Corporation Company Details
12.7.2 Company Description and Business Overview
12.7.3 Immune Check Point Inhibitors Introduction
12.7.4 NewLink Genetics Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.7.5 NewLink Genetics Corporation Recent Development
12.8 Celldex Therapeutics, Inc
12.8.1 Celldex Therapeutics, Inc Company Details
12.8.2 Company Description and Business Overview
12.8.3 Immune Check Point Inhibitors Introduction
12.8.4 Celldex Therapeutics, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.8.5 Celldex Therapeutics, Inc Recent Development
12.9 GlaxoSmithKline plc
12.9.1 GlaxoSmithKline plc Company Details
12.9.2 Company Description and Business Overview
12.9.3 Immune Check Point Inhibitors Introduction
12.9.4 GlaxoSmithKline plc Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.9.5 GlaxoSmithKline plc Recent Development
12.10 Seattle Genetics, Inc.
12.10.1 Seattle Genetics, Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Immune Check Point Inhibitors Introduction
12.10.4 Seattle Genetics, Inc. Revenue in Immune Check Point Inhibitors Business (2014-2019)
12.10.5 Seattle Genetics, Inc. Recent Development
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Table Immune Check Point Inhibitors Key Market Segments
Table Key Players Immune Check Point Inhibitors Covered
Table Global Immune Check Point Inhibitors Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Immune Check Point Inhibitors Market Size Market Share by Type 2014-2025
Figure CLTA-4 Inhibitors Figures
Table Key Players of CLTA-4 Inhibitors
Figure PD-1 & PD-L1 Inhibitor Figures
Table Key Players of PD-1 & PD-L1 Inhibitor
Table Global Immune Check Point Inhibitors Market Size Growth by Application 2014-2025 (Million US$)
Figure Lung Cancer Case Studies
Figure Blood Cancer Case Studies
Figure Renal Cancer Case Studies
Figure Bladder Cancer Case Studies
Figure Melanoma Case Studies
Figure Hodgkin Lymphoma Case Studies
Figure Immune Check Point Inhibitors Report Years Considered
Table Global Immune Check Point Inhibitors Market Size 2014-2025 (Million US$)
Figure Global Immune Check Point Inhibitors Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Immune Check Point Inhibitors Market Size by Regions 2014-2025 (Million US$)
Table Global Immune Check Point Inhibitors Market Size by Regions 2014-2019 (Million US$)
Table Global Immune Check Point Inhibitors Market Share by Regions 2014-2019
Figure Global Immune Check Point Inhibitors Market Share by Regions 2014-2019
Figure Global Immune Check Point Inhibitors Market Share by Regions 2019
Table Market Top Trends
Table Global Immune Check Point Inhibitors Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Immune Check Point Inhibitors Market Share by Manufacturers (2014-2019)
Figure Global Immune Check Point Inhibitors Market Share by Manufacturers in 2018
Table Global Immune Check Point Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Immune Check Point Inhibitors Product/Solution/Service
Table Date of Enter into Immune Check Point Inhibitors Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table Global Immune Check Point Inhibitors Market Size Share by Type (2014-2019)
Figure Global Immune Check Point Inhibitors Market Size Market Share by Type (2014-2019)
Table Global Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table Global Immune Check Point Inhibitors Market Size Share by Application (2014-2019)
Figure Global Immune Check Point Inhibitors Market Size Market Share by Application (2014-2019)
Figure Global Immune Check Point Inhibitors Revenue Market Share by Application in 2018
Figure United States Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table United States Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table United States Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table United States Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table United States Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table United States Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table United States Immune Check Point Inhibitors Market Share by Application (2014-2019)
Figure Europe Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table Europe Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table Europe Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table Europe Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table Europe Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table Europe Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table Europe Immune Check Point Inhibitors Market Share by Application (2014-2019)
Figure China Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table China Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table China Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table China Immune Check Point Inhibitors Market Size by Type (2014-20189) (Million US$)
Table China Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table China Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table China Immune Check Point Inhibitors Market Share by Application (2014-2019)
Figure Japan Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table Japan Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table Japan Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table Japan Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table Japan Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table Japan Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table Japan Immune Check Point Inhibitors Market Share by Application (2014-2019)
Figure Southeast Asia Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table Southeast Asia Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table Southeast Asia Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Immune Check Point Inhibitors Market Share by Application (2014-2019)
Figure India Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table India Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table India Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table India Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table India Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table India Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table India Immune Check Point Inhibitors Market Share by Application (2014-2019)
Figure Central & South America Immune Check Point Inhibitors Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Immune Check Point Inhibitors Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Immune Check Point Inhibitors Market Share (2018-2019)
Table Central & South America Immune Check Point Inhibitors Market Size by Type (2014-2019) (Million US$)
Table Central & South America Immune Check Point Inhibitors Market Share by Type (2014-2019)
Table Central & South America Immune Check Point Inhibitors Market Size by Application (2014-2019) (Million US$)
Table Central & South America Immune Check Point Inhibitors Market Share by Application (2014-2019)
Table Bristol-Myers Squibb Company Company Details
Table Bristol-Myers Squibb Company Revenue in Immune Check Point Inhibitors Business (2014-2019) (Million US$)
Figure Bristol-Myers Squibb Company Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table Bristol-Myers Squibb Company Recent Development
Table AstraZeneca plc Company Details
Table AstraZeneca plc Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure AstraZeneca plc Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table AstraZeneca plc Recent Development
Table Merck & Co Company Details
Table Merck & Co Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure Merck & Co Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table Merck & Co Recent Development
Table Pfizer, Inc Company Details
Table Pfizer, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure Pfizer, Inc Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table Pfizer, Inc Recent Development
Table F. Hoffmann-La Roche Ltd Company Details
Table F. Hoffmann-La Roche Ltd Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure F. Hoffmann-La Roche Ltd Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table F. Hoffmann-La Roche Ltd Recent Development
Table Incyte Corporation Company Details
Table Incyte Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure Incyte Corporation Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table Incyte Corporation Recent Development
Table NewLink Genetics Corporation Company Details
Table NewLink Genetics Corporation Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure NewLink Genetics Corporation Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table NewLink Genetics Corporation Recent Development
Table Celldex Therapeutics, Inc Company Details
Table Celldex Therapeutics, Inc Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure Celldex Therapeutics, Inc Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table Celldex Therapeutics, Inc Recent Development
Table GlaxoSmithKline plc Company Details
Table GlaxoSmithKline plc Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure GlaxoSmithKline plc Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table GlaxoSmithKline plc Recent Development
Table Seattle Genetics, Inc. Company Details
Table Seattle Genetics, Inc. Revenue in Immune Check Point Inhibitors Business (2014-2019)(Million US$)
Figure Seattle Genetics, Inc. Revenue Growth Rate in Immune Check Point Inhibitors Business (2014-2019)
Table Seattle Genetics, Inc. Recent Development
Table Global Immune Check Point Inhibitors Market Size by Regions (Million US$) 2019-2025
Figure Global Immune Check Point Inhibitors Market Size Share by Regions (2019-2025)
Figure Global Immune Check Point Inhibitors Market Size Share by Regions in 2025
Figure United States Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Europe Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure China Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Japan Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure India Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Immune Check Point Inhibitors Market Size Forecast (2019-2025)(Million USD)
Table Global Immune Check Point Inhibitors Market Size by Product (2019-2025) (Million US$)
Figure Global Immune Check Point Inhibitors Market Size by Product (2019-2025)
Figure Global Immune Check Point Inhibitors Market Size by Product in 2025
Table Global Immune Check Point Inhibitors Market Size by Application (2019-2025) (Million US$)
Figure Global Immune Check Point Inhibitors Market Size by Application (2019-2025)
Figure Global Immune Check Point Inhibitors Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
がん免疫療法の世界市場：市場規模・現状・予測 Cancer immunotherapy is a type of cancer treatment that boosts the human bodys natural immune system to fight against the cancer cells. This therapy is provided to cancer patients to stop the spread of cancer, to slow down the growth of cancer cells, and to improve the natural immunity for destroyin…- 膀胱がん治療の世界市場：市場規模・現状・予測 The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…
- 膀胱がん臨床試験の世界市場：市場規模・現状・予測 Bladder Cancer Clinical trials are research studies that involve people. The clinical trials on this list are for bladder cancer treatment. ... This randomized phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread from where it started to nearb…
- 非黒色腫皮膚癌の世界市場：市場規模・現状・予測 Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts.Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikel…
- 世界の未分化リンパ腫キナーゼ阻害剤市場：動向・競争分析 ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[In 2018, the global Anaplastic Lymphoma Kinase Inhibitors market size was xx million US$ and is forecast to xx million US in 2025, growing at a CA…